The unregulated peptide market has two tiers. 'Gray market' sources, often sold for 'research only,' typically provide 99% purity data sheets, confirming the substance's identity despite contamination risks. 'Black market' sources offer no verification, meaning the vial's contents are completely unknown and far riskier.

The pro-peptide argument isn't that these substances are proven cures, but that a regulated "white market" is safer than the current gray market. By moving production to GMP-certified compounding pharmacies under FDA oversight, the goal is to reduce harm from a dodgy, unregulated supply chain that already exists.

Many peptides are unlikely to ever receive FDA approval because their simple, easily replicated structures make them commodities. Pharma companies won't fund billion-dollar trials for drugs they can't patent, leaving them in a permanent gray market.

In the absence of formal regulation, peptide users have created a decentralized trust system. They import substances from gray-market Chinese suppliers and then pay independent US or European labs to verify purity, creating a crowdsourced quality control process.

The critique of the peptide trend often misses that users aren't taking unknown chemicals. Many use compounds like Retatrutide, which is already in Phase 3 clinical trials by Eli Lilly. They are essentially front-running the FDA approval process for drugs that already have substantial clinical backing.

The disagreement over peptides is a philosophical split. One side values strong anecdotal results and personal experimentation, accepting the risks of the 'unknown unknowns.' The other side demands long-term, FDA-approved studies and regulatory oversight, viewing anything less as reckless and driven by psychology rather than science.

The demand for unregulated peptides isn't just from niche biohackers; it's also from older individuals seeking relief for conditions like chronic joint pain where traditional medicine offers few effective solutions. This highlights a significant unmet need driving patients to experimental substances.

Andrew Huberman suggests that an impending crackdown on gray market peptides is motivated by pharmaceutical giant Eli Lilly's desire to protect its patent on Retatrutide, a potential trillion-dollar weight-loss drug. The push for regulation may be less about public safety and more about eliminating low-cost, gray-market alternatives to a blockbuster product.

The six peptides under FDA consideration are "naked," lacking the chemical enhancements of modern peptide drugs like GLP-1s. This simple structure causes them to break down very quickly in the body, likely before they can produce any meaningful biological effect, rendering them potentially expensive placebos.